Lung Cancer Test Articles & Analysis
6 news found
The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. ...
Abstract title: “Metabolomic Profiling for the Early Detection of Lung Cancer”. The results demonstrated the high accuracy of BioMark’s quantitative metabolomic platform to identify early-stage lung cancer in retrospective plasma samples from individual with smoking history compared to participants suffering ...
The Company will be presenting clinical data using its quantitative metabolomic platform to identify early-stage lung cancer in retrospective plasma samples from individual with smoking history, or suffering from other lung diseases including asthma, COPD, bronchiectasis and COVID. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate ...
(“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. ...
Nucleix will utilize the proceeds of the financing to continue the rapid advancement of its unique methylation technology, known as EpiCheck®, and to develop Lung EpiCheck®, its lead product for the early detection of lung cancer. ...